Eli Lilly

Covance Finalizes Merck Deal, Delays Construction of Preclinical Unit

Thursday, August 20, 2009 06:35 AM

Covance officially closed a deal with Merck earlier this week to provide genomics analysis services to the drug developer for the next five years. Under the terms of the $145-million agreement, the contract research organization (CRO) acquired Merck’s Seattle-based Gene Expression Laboratory. All Merck employees related to the Seattle facility became Covance employees as of August 17.

More... »

ICON Inks Exclusive European Deal with Lilly

Monday, June 15, 2009 07:00 AM

Dublin, Ireland-based contract research organization (CRO) ICON expanded its outsourcing relationship with Eli Lilly and Company last week, as the two companies teamed up in an exclusive strategic partnership in Europe.

More... »

PPD Acquires Magen BioSciences, Plans to Sell Piedmont Research

Friday, April 3, 2009 02:00 PM

PPD acquired Magen BioSciences, a dermatology-focused biotechnology company—just as the contract research organization (CRO) announced plans to divest its preclinical research subsidiary Piedmont Research Center.

More... »

PPD and Merck in Strategic Outsourcing Deal

Tuesday, January 6, 2009 11:25 AM

Contract research organization (CRO) PPD has entered into a strategic collaboration with Merck that will significantly expand PPD’s global central laboratory business.

More... »

Conflict of Interest Case Could Change Disclosure Rules

Tuesday, October 14, 2008 06:37 AM

The congressional investigation into an influential psychiatrist’s failure to disclose more than a million dollars in drugmaker payments is the latest in a spate of conflict-of-interest investigations that may force changes in the way financial disclosures are handled.

More... »

CenterWatch Monthly October 2008

Friday, October 3, 2008 02:44 PM

Trio of Companies in Strategic Outsourcing Partnerships with Lilly

More... »

Covance, Lilly Deal Grows on CRO Industry

Friday, August 8, 2008 05:00 PM

Earlier this week, we reported news about the Covance-Lilly $1.6-billion deal, but Clinicaltrialstoday.com has learned additional details about the blockbuster transaction between the contract research organization (CRO) and major pharma company from interviews and Wednesday’s investor conference call.

More... »

Kendle's Global CRO Growth Story Continues with Record Quarter

Thursday, August 7, 2008 07:30 AM

On a day when contract research organization (CRO) Covance announced a blockbuster $1.6 billion deal with Eli Lilly, the global CRO growth story got another big boost when Kendle reported record financial results for its second quarter.

More... »

Covance in Groundbreaking $1.6 Billion Drug Development Services Deal with Eli Lilly

Wednesday, August 6, 2008 09:44 AM

Covance, a leading global contract research organization (CRO), signed a definitive agreement today with Eli Lilly that is designed to help transform Lilly’s R&D model.

More... »

Cymbalta Reduces Pain in Fibromyalgia Trial

Tuesday, August 28, 2007 03:56 PM

Eli Lilly reported positive results from a phase III trial of Cymbalta (duloxetine) for the treatment of fibromyalgia. Cymbalta is Lilly’s serotonin and norepinephrine reuptake inhibitor (SSNRI), approved in the U.S. for major depression and diabetic (peripheral neuropathic) pain. Merrill Lynch has forecasted the product could reach worldwide sales of $2.2 billion in 2008.

More... »